Short Summary
The Delhi High Court dismissed Biofarma's suit against Bal Pharma Limited concerning passing off and trade dress infringement. The court found that the plaintiff could not claim exclusive rights over the term 'MEX' because it was an acronym ('Metformin Extended Release') derived from the principal drug ingredient, rendering it descriptive and publici juris in the pharmaceutical trade. Consequently, the defendant was permitted to continue using the mark without infringing on the plaintiff’s established brand.
Detailed Summary
In the fiercely competitive pharmaceutical industry, brand names are often treated like crown jewels. But what happens when a company tries to claim ownership over a tiny, three-letter abbreviation that simply describes what the drug actually does? The Delhi High Court faced exactly this question in a dispute that serves as a sharp reminder for every founder building a brand in the healthcare space: not every word you use can be yours alone.
Biofarma, the plaintiff, had built a pharmaceutical product around the term 'MEX.' When Bal Pharma Limited, the defendant, began marketing a similar product using the same 'MEX' mark, Biofarma swung into legal action. The plaintiff alleged that Bal Pharma was guilty of passing off and trade dress infringement, arguing that 'MEX' was its established brand and that the rival's use of it would confuse customers and dilute Biofarma's hard-earned reputation in the market. The dispute landed before the Delhi High Court on 22 November 2018, putting the spotlight on a fundamental question of trademark law in the pharmaceutical sector.
Biofarma argued that 'MEX' was its proprietary mark, closely associated with its product, and that Bal Pharma's adoption of the same term amounted to unfair competition and infringement of its trade dress. The company positioned itself as the rightful owner of the brand identity built around the abbreviation. Bal Pharma, on the other hand, countered that 'MEX' was not a fanciful invention but a descriptive acronym standing for 'Metformin Extended Release' — a direct reference to the principal active ingredient and the formulation type of the drug itself. The defendant argued that such a term was descriptive in nature and belonged to the public domain, meaning no single company could monopolize it.
The Delhi High Court sided with Bal Pharma and dismissed Biofarma's suit. The court reasoned that 'MEX' was an acronym derived directly from the drug's principal ingredient — 'Metformin Extended Release' — making it descriptive and publici juris, a term belonging to the common trade rather than any individual proprietor. Because the abbreviation was rooted in the inherent nature of the pharmaceutical product itself, Biofarma could not claim exclusive rights over it. The court held that allowing one company to monopolize such a descriptive term would unfairly block competitors from accurately describing their own formulations. As a result, Bal Pharma was permitted to continue using the 'MEX' mark without any finding of infringement or passing off.
For founders and IP professionals in the pharmaceutical sector, this case delivers a clear and practical lesson: descriptive abbreviations or terms that directly reference a drug's active ingredient or formulation type generally fall into the public domain and cannot be monopolized as trademarks. When building a brand around a pharmaceutical product, invest in distinctive, fanciful, or arbitrary marks rather than acronyms that merely describe what the drug does. Otherwise, you risk investing heavily in brand equity around a name that the law will ultimately consider free for any competitor to use.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in trademark matters before Delhi High Court. Understanding the court's reasoning in Biofarma vs Bal Pharma Limited is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Mahesh Namkeen Pvt. Ltd.vsOm Prakash Nebhwani (Trading as: Mahesh Matar Namkeen)
Mahesh Namkeen Pvt. Ltd., a Lucknow-based company engaged in manufacturing namkeens and snacks since 1983 under the trademark 'MAHESH' (with parrot device), sued Om Prakash Nebhwani for trademark infringement and passing off. The defendant, who is the nephew of the plaintiff's director and had prior knowledge of the mark, adopted the identical 'MAHESH' mark with parrot/peacock device for his own namkeen business in Jaipur. The defendant's defense was struck off for non-filing of written statement. The court found the plaintiff's mark to be distinctive, well-established, and a well-known trademark, and held that the defendant's use constituted slavish copying amounting to infringement and passing off.
Ms Pas AgrovsM/S Krbl Limited & Anr
Ms Pas Agro has filed a petition under Section 124(1)(b)(ii) of the Trademarks Act challenging the Commercial Court's order dismissing its application to frame a preliminary issue on the invalidity of KRBL's registered trademark 'INDIA GATE' (application no. 599833). The underlying suit CS (COMM) 78/2025 was filed by KRBL against Pas Agro. The Delhi High Court issued notice, permitted deletion of respondent no.2, and granted time for filing reply and rejoinder. The substantive question of whether a preliminary issue on trademark invalidity should be framed remains pending.
Cryogas Equipment Private LimitedvsInox India Limited & Ors.
The Supreme Court disposed of a miscellaneous application seeking extension of time for the trial court to decide Trademark Suit No. 3 of 2019 between Cryogas Equipment Private Limited and Inox India Limited. As a last opportunity, the Court granted an additional six months to the concerned court to decide the suit, while expressly warning that no further extension would be entertained. The underlying dispute concerns trademark rights in the cryogenic/industrial gas equipment sector.
Mankind Consumer Products Private LimitedvsAlaina Healthcare Private Limited & A. Menarini India Private Limited
Mankind Consumer Products, the registered proprietor of the trademark ACNESTAR (Reg. No. 1352577 in Class 5) since 2005, sued Alaina Healthcare and A. Menarini India for using the marks ACNE SCAR/ACNE+SCAR/ACNESCAR on their acne scar serum product HEXILAK. The court found a prima facie case of deceptive similarity, noting that the dominant feature 'ACNE' was common and the suffix 'STAR' vs 'SCAR' was insufficient to distinguish the marks, especially given the identical trade channels and consumer class. The court granted an interim injunction in favour of the plaintiff while allowing defendant no. 2 a two-month period to recall existing stock from the trade.
Healthium Medtech Limited (earlier Healthium Medtech Private Limited)vsThe Registrar of Trade Marks, Chennai
Healthium Medtech Limited filed a writ petition seeking a mandamus to compel the Registrar of Trade Marks to expeditiously dispose of Opposition No. 1027536 filed by Glenmark Pharmaceuticals against Healthium's trademark application No. 4270882 for the 'Healthium' device mark in Classes 05 and 10. The petitioner complained that despite evidence having been adduced, the opposition proceedings remained pending without a final hearing. The Madras High Court allowed the writ petition and directed the Registrar to hear both parties and dispose of the opposition on merits within four weeks.
CavinKare Private LimitedvsMaha Aqua, Trading As Mahalakshmi Aqua
CavinKare Private Limited filed a trademark infringement suit against Maha Aqua (trading as Mahalakshmi Aqua) seeking a permanent injunction to restrain the defendant from using the mark 'MAA' or any deceptively similar mark in respect of goods in Class 32. The plaintiff relies on its registered trademarks 'MAA' under Nos. 1109946 and 6453733. The Court, after issues were framed and affidavits of admission/denial filed, approved a Joint Case Management Schedule suggested by both parties and set timelines for completion of evidence and oral arguments.
Facing a trademark dispute?
Arctic's TM litigation team handles ~120 trademark matters per year across India, EU, and UK. From oppositions to infringement actions, we build winning arguments from precedent.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.